Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its results from its Phase 2 study of VK2809, a non-alcoholic fatty liver treatment. The Company announced positive top-line results, sending shares surging by 140% on Tuesday.
VK2809 is an orally ingested tissue and receptor-subtype selective agonist of the thyroid beta receptor.
The study successfully achieved all primary endpoints, with patients who received the VK2809 demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C) compared to the placebo group. The trial’s secondary endpoints were also met. The treatment also significantly reduced liver fat content in the group who received it.
Specifically, patients who received VK2809 reported a 20% reduction in LDL-C and showed improvements in other lipids, including atherogenic proteins apolipoprotein B and lipoprotein (a).
“This proof-of-concept study demonstrates robust improvement in liver fat by VK2809 versus placebo. The trial utilized a state-of-the-art method, MRI-PDFF, as a non-invasive quantitative biomarker of changes in liver fat content. Previous studies by our group have shown that a 30% or greater reduction in MRI-PDFF is associated with higher odds of histologic response in NASH. The quantum of liver fat reduction along with LDL-lowering properties of VK2809 are potentially likely to be beneficial in patients with non-alcoholic steatohepatitis (NASH) who have a significant risk of not only liver fibrosis progression but also cardiovascular disease,” stated Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, and Professor of Medicine, University of California at San Diego.
The Company is now preparing to evaluate VK2809 in a Phase 1 study for the treatment of patients with GSD la.
Viking Therapeutics’ top results sent its competitor’s, Madrigal Pharmaceuticals (NASDAQ: MDGL), tumbling down by 14% on Tuesday.